REPL Archived Articles
Replimune Group, Inc. (NASDAQ:REPL): Pioneering Oncolytic Immunotherapies to Transform Cancer Treatment
Published on November 17, 2024
Replimune Group, Inc. (NASDAQ:REPL): Pioneering Oncolytic Immunotherapies with Promising Clinical Progress
Published on September 24, 2024